[Systems approach to interferon as an anticancer agent].
Borecký
L
L
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents; D002471:Cell Transformation, Neoplastic / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007107:Immune System / Q000502:physiology; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D007372:Interferons / Q000502:physiology / Q000627:therapeutic use*; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D011379:Prognosis; D011453:Prostaglandins / Q000502:physiology / Q000627:therapeutic use; D011971:Receptors, Immunologic / Q000276:immunology; D017471:Receptors, Interferon; D013597:Systems Analysis; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D011453:Prostaglandins; D011971:Receptors, Immunologic; D017471:Receptors, Interferon; D007372:Interferons
Sistemnyĭ podkhod k interferonu kak protivorakovomu sredstvu.